Univariable analysis | Multivariable analysis* | |||
---|---|---|---|---|
Factors | Odds ratio (95% CI) | p-value | Odds ratio (95% CI) | p-value |
Male | 0.556 (0.143–2.162) | 0.397 | ||
Age (ref. ≥ 70 years) | 0.178 | |||
19 ~ 29 years | 0.143 (0.004–4.612) | |||
30 ~ 39 years | 1.333 (0.057–31.121) | |||
40 ~ 49 years | 0.083 (0.003–2.603) | |||
50 ~ 59 years | 0.571 (0.028–11.849) | |||
60 ~ 69 years | 0.125 (0.004–3.996) | |||
Smoking history | 1.336 (0.334–5.343) | 0.881 | ||
Oral ulcer | 1.454 (0.373–5.679) | 0.590 | ||
Genital ulcer | 1.701 (0.271–10.686) | 0.571 | ||
Ocular lesion | 2.200 (0.440-11.006) | 0.337 | ||
Skin lesion | 4.429 (1.095–17.915) | 0.037 | 3.205 (0.576–17.827) | 0.183 |
Arthralgia | 3.810 (0.901–16.100) | 0.069 | 5.581 (0.894–34.855) | 0.066 |
Previous treatment for BD | 0.081 (0.008–0.874) | 0.038 | 0.062 (0.002–1.682) | 0.099 |
Previous medical history | 0.722 (0.165–3.157) | 0.666 | ||
Concomitant diseases | 0.714 (0.176–2.898) | 0.638 | ||
Concomitant medications | 0.278 (0.035–2.227) | 0.228 | ||
Disease duration (a month) | 0.973 (0.949–0.997) | 0.026 | 0.976 (0.953–0.999) | 0.042 |
Total amount of adalimumab (mg) | 0.999 (0.997–1.001) | 0.251 | ||
Frequency of adalimumab administration (times) | 0.963 (0.900–1.030) | 0.272 |